September 4, 2013
CDT Seminar Series – September 4, 2013
A CDT Special Seminar will be held Wednesday, September 4th, at 1:00pm at the Petit Science Center in PSC124. Please join us to hear Dr. James Lillard (http://www.msm.edu/academic/microbiology/faculty/James_Lillard.aspx) from the Department of Microbiology, Biochemistry & Immunology at Morehouse School of Medicine. His talk is entitled “XPclad Nanoreformulation of Cisplatin for Prostate Cancer”.
James Lillard rejoined Morehouse School of Medicine’s faculty as Professor of Microbiology, Biochemistry, & Immunology and Assistant Dean for Research in November 2009. Previously, Dr.Lillard was the Smith & Lucille Gibson Endowed Chair in Medicine, Senior Scientist at the James Graham Brown Cancer Center, and Vice Chair for Research as well as Professor in the Department of Microbiology & Immunology at the University of Louisville from 2006 to 2009. In July 2011, Morehouse School of Medicine Dr. Lillard established the Office of Translational Technologies, where he serves as its Director. He also serves as the Director of the Cancer Research Program, Director of the GRA VentureLab, and the Associate Dean for Research Affairs at Morehouse School of Medicine.
Dr. Lillard completed his B.S. degree in Electrical Engineering & Computer Science from the Ohio State University in 1988 and worked as a product development engineer for IBM from 1988 to 1992. He received his Ph.D. in Microbiology & Immunology from the University of Kentucky School of Medicine, where he studied Yersinia “plague” pathogenesis from 1992 to 1996 under the direction of Robert Perry, Ph.D. Dr. Lillard completed his post-doctoral training from 1996 to 1999 in mucosal immunology under the direction of Jerry McGhee, Ph.D. at the University of Alabama at Birmingham in the Department of Microbiology. Subsequently, he worked as an Assistant and Associate Professor in the Department of Microbiology, Biochemistry, and Immunology at MSM from 1999 to 2006 and completed an Executive MBA focused on Biotechnology & Healthcare from the Goizueta Business School at Emory University from 2001 to 2002.
Dr. Lillard is an immuno-biologist that uses both in silico and in vivo methods to develop biologics, humanized antibodies, vaccines, and nanoparticles to diagnose, prevent, and/or treat (prostate, breast, and ovarian) cancer and infectious diseases. His research contributions span multiple disciplines including oncology, vaccine development, biodefense, and neuro-inflammation. Dr. Lillard’s cumulative peer-reviewed funding principally directed over his scientific career exceeds $22m and he has authored over 302 scientific communications, which have been cited over 2,500 times. These communications include: 62 publications, 83 patent applications (including 21 issued patents), 65 invited lectures, and 92 poster presentations. Dr. Lillard’s articles have appeared in International Journal of Cancer Research, Clinical Cancer Research, Journal of Clinical Investigations, Journal Immunology, Laboratory Investigations, and Proceedings of the National Academy of Sciences USA. His work is nationally and internationally recognized as indicated by his service on editorial boards and scientific review for the National Institutes of Health, Department of Defense, and United States Food & Drug Administration advisory panels and study sections. Dr. Lillard’s long-term career goals are to be actively involved in academic research and teaching, while contributing to enterprises that can benefit from his background expertise and experiences.